A Review of Bullous Dermatologic Adverse Events Associated with Anti-Cancer Therapy
Open Access
- 24 January 2023
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 11 (2) , 323
Abstract
The rapid evolution of anti-cancer therapy (including chemotherapy, targeted therapy, and immunotherapy) in recent years has led to a more favorable efficacy and safety profile for a growing cancer population, and the improvement of overall survival and reduction of morbidity for many cancers. Anti-cancer therapy improves outcomes for cancer patients; however, many classes of anti-cancer therapy have been implicated in the induction of bullous dermatologic adverse events (DAE), leading to reduced patient quality of life and in some cases discontinuation of life-prolonging or palliative therapy. Timely and effective management of adverse events is critical for reducing treatment interruptions and preserving an anti-tumor effect. Bullous DAE may be limited to the skin or have systemic involvement with greater risk of morbidity and mortality. We present the epidemiology, diagnosis, pathogenesis, and management of bullous DAE secondary to anti-cancer therapies to enable clinicians to optimize management for these patients.Keywords
Funding Information
- NIH/NCI Cancer Center (P30 CA008748)
This publication has 115 references indexed in Scilit:
- Clinical Presentation and Management of Hand–Foot Skin Reaction Associated with Sorafenib in Combination with Cytotoxic Chemotherapy: Experience in Breast CancerThe Oncologist, 2011
- Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon?Targeted Oncology, 2009
- Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimensCancer Chemotherapy and Pharmacology, 2009
- Toxic erythema of chemotherapy: A useful clinical termJournal of the American Academy of Dermatology, 2008
- TLR7 and TLR8 as targets in cancer therapyOncogene, 2008
- Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapyBritish Journal of Dermatology, 2007
- Palmar–plantar erythrodysesthesia (PPE): A literature review with commentary on experience in a cancer centreEuropean Journal of Oncology Nursing, 2007
- Bullous dermatosis associated with gemcitabine therapy for non-small-cell lung carcinomaRespiratory Medicine, 2006
- Stevens–Johnson syndrome/toxic epidermal necrolysis in a patient receiving concurrent radiation and gemcitabineAnti-Cancer Drugs, 2003
- Unusual reaction to chlorambucil: a case reportCancer Letters, 1990